Physiological and QoL Benefits of Qi-Gong in Post-acute Sequelae of Covid-19

Not Applicable

Recruiting

• Conditions: PASC Post Acute Sequelae of COVID 19

• Registration Number: NCT06879925
• Lead Sponsor: POCHIWU

Brief Summary

The goal of this clinical trial is to determine whether Qi-Gong can improve physiological function and quality of life (QoL) in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC).

Study Objectives:

To assess whether Qi-Gong improves physiological function in individuals with PASC.

To evaluate whether Qi-Gong enhances quality of life in individuals with PASC.

Study Design:

If a comparison group is included, researchers will compare Qi-Gong with standard care to assess its effectiveness.

Participant Involvement:

Practice Qi-Gong three times per week for three months. Record physiological data monthly.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-12-02
• Study First Submitted: 2025-02-15
• Status Verified: 2025-03
• Study First Submitted QC: 2025-03-12
• Last Update Submitted: 2025-03-12
• Study First Posted: 2025-03-17
• Last Update Posted: 2025-03-17
• Primary Completion: 2025-04-07
• Study Completion: 2025-04-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• PASC
• above 20 y/o

Exclusion Criteria

• Those who cannot cooperate
• Severe schizophrenia

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Pulmonary Function Test (Forced vital capacity)	From enrollment to the end of treatment at 12 weeks	FVC，over 80% is better
Quality of Life(The short version of the World Health Organization Quality of Life ，WHOQOL-BREF)	From enrollment to the end of treatment at 12 weeks	WHOQOL-BREF 4 domains,and each one score is 4 - 20. more score more better
Pulmonary Function Test (FEV1)	From enrollment to the end of treatment at 12 weeks	FEV1，over 80% is better
Pulmonary Function Test (FVCFEV1)	From enrollment to the end of treatment at 12 weeks	FVCFEV1，over 80% is better
Heart rate variability	From enrollment to the end of treatment at 12 weeks	Heart rate variability ,25ms-70ms

Trial Locations

Locations (2)

Renhe nursing home; 🇨🇳 New Taipei City, Taiwan

Fuxi nursing home; 🇨🇳 Taipei, Taiwan